VK2735 for Weight Loss: A Dual GIP/GLP-1 Agonist in Oral and Injectable Development

Candidate profile

Conceptually, the population of interest for VK2735 is the same broad group now treated with incretin-based obesity drugs: adults with obesity, or overweight with weight-related complications. What makes VK2735 notable is that Viking Therapeutics is developing it in an oral tablet as well as a subcutaneous injectable — which would matter most to people who want the efficacy of an incretin drug without injections.

But the framing has to come first: VK2735 is investigational. There is no "candidate" for it outside a clinical trial, because it is not approved or available. This use case is about understanding a promising drug in development, not a treatment anyone can access today.

Why the mechanism is interesting

VK2735 activates two receptors from one molecule: the GLP-1 receptor and the GIP receptor. GLP-1 agonism reduces appetite, slows gastric emptying, and improves glucose handling; GIP agonism adds complementary metabolic effects. Engaging both is the same dual-incretin strategy that made tirzepatide the benchmark — the rationale being that two pathways together drive deeper weight loss than GLP-1 alone.

VK2735 pursues that validated mechanism as a distinct molecule, with the added ambition of an oral formulation.

What the early data suggest

Early-phase trials of the subcutaneous form reported clinically meaningful mean weight reductions over roughly a few months, and a separate oral program has reported encouraging early weight-loss signals. As expected for the class, gastrointestinal effects (nausea, vomiting, reduced appetite) were the most common findings, concentrated during dose escalation.

These are genuinely promising signals — but they come from small, short, early-phase studies. They indicate potential, not confirmed efficacy. Whether VK2735 produces large, durable weight loss with acceptable tolerability can only be established by larger, longer randomized phase 2 and phase 3 trials, which is the standard every drug in this space must clear.

Why an oral incretin matters

Peptides are normally hard to absorb through the gut, so an orally available incretin agent is scientifically notable and commercially significant: it could broaden access for people unwilling or unable to inject. Several programs (including oral semaglutide, orforglipron, and amycretin's oral form) are chasing this goal. VK2735's parallel oral-and-injectable development is a key reason for the attention it receives — but the oral form is investigational and unproven like the injectable.

Where it fits among the new obesity drugs

VK2735 is one of several next-generation incretin candidates competing to follow semaglutide and tirzepatide:

• VK2735 — dual GIP/GLP-1 (like tirzepatide), with an oral program.
• Retatrutide — triple GIP/GLP-1/glucagon agonist.
• Orforglipron — oral non-peptide GLP-1 agonist.
• Amycretin — GLP-1/amylin co-agonist, oral and injectable.

All are investigational except the already-approved agents, and there are no head-to-head trials, so cross-drug comparisons are inferential.

Honest limitations

• Investigational and unapproved everywhere; long-term safety is not established.
• Data are early-phase — small and short — so effect sizes may shift with larger trials.
• Not legally available; any product sold as "VK2735" outside a trial should be treated as illegitimate and unsafe, with unknown purity and dosing.

The takeaway

VK2735 is a credible next-generation dual agonist whose parallel oral and injectable development makes it one of the more closely watched names in obesity medicine. The early weight-loss signals are encouraging, but this is firmly a science-to-watch story: the gap between promising early data and an approved, well-characterized treatment is exactly where many candidates stall. For now, VK2735 is worth understanding, not pursuing.

This article is educational and does not constitute medical advice. Obesity treatment decisions belong with a qualified clinician using approved therapies.